Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Unravel licenses technology from Harvard’s Wyss Institute

by Shi En Kim
October 1, 2022 | A version of this story appeared in Volume 100, Issue 35

 

Unravel Biosciences has licensed technology invented at Harvard University’s Wyss Institute for developing therapies for diseases affecting the central nervous system. The technology uses automated assays to screen for drug efficacy in tadpoles that have been CRISPR modified to bear the genetic signatures of a disease. The company, which was founded by several Wyss scientists, is first targeting Rett syndrome, a rare genetic disorder that causes progressive loss in motor and intellectual function, predominantly in girls.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.